The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Abstract
IMPORTANCE: Ipilimumab and other immune therapies are effective treatment options for patients with advanced melanoma but cause frequent immune-related toxic effects. Autoimmune diseases are common, and the safety and efficacy of ipilimumab therapy in patients with preexisting autoimmune disorders is not known. OBJECTIVE: To determine the safety and efficacy of ipilimumab therapy in patients with advanced melanoma with preexisting autoimmune disorders. DESIGN, SETTING, AND PARTICIPANTS: Retrospective review of patients with advanced melanoma and preexisting autoimmune disorders who received ipilimumab at 9 academic tertiary referral centers from January 1, 2012, through August 1, 2015. The data analysis was performed on August 24, 2015. EXPOSURE: Ipilimumab therapy. MAIN OUTCOMES AND MEASURES: Safety, in terms of frequency of autoimmune flares and conventional immune-related adverse events (irAEs), and efficacy, in terms of response rates and overall survival, were evaluated descriptively. RESULTS: Of the 30 patients who received ipilimumab (17 [57%] male; median [range] age, 59.5 [30-80] y), 6 had rheumatoid arthritis, 5 had psoriasis, 6 had inflammatory bowel disease, 2 had systemic lupus erythematosus, 2 had multiple sclerosis, 2 had autoimmune thyroiditis, and 7 had other conditions. Thirteen patients (43%) were receiving immunosuppressive therapy at the time of initiation of ipilimumab therapy, most commonly low-dose prednisone or hydroxychloroquine. With ipilimumab treatment, 8 patients (27%) experienced exacerbations of their autoimmune condition necessitating systemic treatment; all were managed with corticosteroids. Conventional grade 3 to 5 irAEs occurred in 10 patients (33%) and were reversible with corticosteroids or with infliximab therapy in 2 cases. One patient with baseline psoriasis died of presumed immune-related colitis after a 1-week delay prior to reporting symptoms. Fifteen patients (50%) had neither autoimmune disease flares nor irAEs. Six patients experienced an objective response (20%), including 1 with a durable complete response. CONCLUSIONS AND RELEVANCE: To our knowledge, this is the largest series of patients with preexisting autoimmune disease treated with immune checkpoint inhibitors. Ipilimumab was clinically active and was associated with exacerbations of autoimmune disease and conventional ipilimumab-induced irAEs that were readily manageable with standard therapies when started in a timely fashion. Ipilimumab therapy may be considered in this setting with vigilant clinical monitoring.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Possible risk factors for ICI-related hepatotoxicity include organ transplantation, comorbidity with autoimmune disease, history of ICI-induced irAEs, high doses of ICIs (particularly cytotoxic T-lymphocyte antigen 4 inhibitors), combination therapy with multiple ICIs, or a combination of an ICI with targeted therapy [165][166][167].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [165]
In the citing paper
“Incidence of endocrine events varies based on type of ICI used (see Figure 2).38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [38]
In the citing paper
“Thyroid events occur in approximately 10% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 15-20% of those treated with combination PD-1/CTLA-4 blockade (as opposed to only 5% of those treated with ipilimumab monotherapy).9,38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [38]
In the citing paper
“hypophysitis or hypopituitarism occurs in up to 10% of patients who receive anti-CTLA-4 based therapy (either with ipilimumab monotherapy, and slightly more commonly with combination CTLA-4/PD-1 blockade).38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [38]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
The mortality of rheumatoid arthritis
Wolfe, F., Mitchell, D. M., Sibley, J. T., Fries, J. F., Bloch, D. A., Williams, C. A., Spitz, P. W., Haga, M., Kleinheksel, S. M., & Cathey, M. A. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370408 · Cited by 1,325
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70122-1 · Cited by 1,262
Cited by
Sorted by citations
Items 301–400 of 639
Yin, J., Elias, R. M., Peng, L., Levonyak, N. S., Asokan, A., Christie, A. L., Kubiliun, N. M., Brugarolas, J., & Hammers, H. J. (2022) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2022.01.017 · Cited by 23
Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus
Kani, E.-R., Karaviti, E., Karaviti, D., Gerontiti, E., Paschou, I. A., Saltiki, K., Stefanaki, K., Ψαλτοπούλου, Θ., & Paschou, S. Α. (2024) · Endocrine · doi:10.1007/s12020-024-04050-5 · Cited by 22
The Second Wave of Immune Checkpoint Inhibitor Tsunami: Advance, Challenges and Perspectives
Kourié, H. R., Awada, G., & Awada, A. H. (2017) · Immunotherapy · doi:10.2217/imt-2017-0029 · Cited by 24
Khan, S. A., Pruitt, S. L., Xuan, L., Makris, U. E., & Gerber, D. E. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.024 · Cited by 22
Su, Q., Zhang, X., Wang, D., Zhang, H., Zhu, C. G., Hou, Y., Liu, J., & Gao, Z. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.04.021 · Cited by 22
Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis
Sher, A. F., Golshani, G. M., & Wu, S. (2020) · Cancer Investigation · doi:10.1080/07357907.2020.1721521 · Cited by 22
Quiruz, L. A., Yavari, N., Kikani, B., Gupta, A., Wai, K. M., Kossler, A. L., Ludwig, C. A., Koo, E., Rahimy, E., & Mruthyunjaya, P. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.08.044 · Cited by 21
Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence
Eshaq, A. M., Flanagan, T. W., Abbad, A. A. B., Makarem, Z. A. A., Bokir, M. S., Alasheq, A. K., Asheikh, S. A. A., Almashhor, A. M., Binyamani, F., Al-Amoudi, W. A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010088 · Cited by 23
Zhou, H., Fu, X., Li, Q., & Niu, T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00387 · Cited by 21
Diagnosis, Monitoring, and Management of Adverse Events From Immune Checkpoint Inhibitor Therapy
Khan, O. F., & Monzon, J. G. (2020) · Current Oncology · doi:10.3747/co.27.5111 · Cited by 21
Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis
Kaulen, L. D., Karschnia, P., Dietrich, J., & Baehring, J. M. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03583-9 · Cited by 21
Suarez-Almazor, M. E., Pundole, X., Abdel‐Wahab, N., Johnson, D. B., Gupta, D., Glezerman, I. G., Cooksley, T., Anderson, R., Blidner, A. G., Choi, J. N., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05710-8 · Cited by 21
Self-citationImmune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy
Le, J., Sun, Y., Deng, G., Dian, Y., Xie, Y., & Zeng, F. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2458948 · Cited by 22
Grimsdottir, S., Attauabi, M., Dahl, E. K., Burisch, J. M., & Seidelin, J. B. (2023) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjad010 · Cited by 20
Hein, E. C. K., Vilbert, M., Hirsch, I., Ribeiro, M. F. S. A., Muniz, T. P., Fournier, C., Abdulalem, K., Saldanha, E. F., Martinez, E. A., Spreafico, A., et al. (2023) · Cancers · doi:10.3390/cancers15174312 · Cited by 21
Immune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune Disorders
Aoun, R., Gratch, D., Kaminetzky, D., & Kister, I. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01306-x · Cited by 20
Immune Checkpoint Inhibitors and Lupus Erythematosus
von Eckstaedt, H. V., Singh, A., Reid, P. D., & Trotter, K. C. (2024) · Pharmaceuticals · doi:10.3390/ph17020252 · Cited by 20
Refractory myasthenia gravis exacerbation triggered By pembrolizumab
Earl, D. E., Loochtan, A. I., & Bedlack, R. (2017) · Muscle & Nerve · doi:10.1002/mus.26021 · Cited by 20
Nabel, C. S., Severgnini, M., Hung, Y. P., Cunningham‐Bussel, A., Gjini, E., Kleinsteuber, K., Seymour, L., Holland, M., Cunningham, R., Felt, K. D., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0633 · Cited by 20
Sebastiani, G. D., Scirocco, C., & Galeazzi, M. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.06.005 · Cited by 20
The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy
Medina, P. J., Jeffers, K. D., Trinh, V. A., & Harvey, R. D. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019885230 · Cited by 21
Use of Immune Checkpoint Inhibitors in Cancer Patients with Pre-Existing Sarcoidosis
Kim, S. T., Pundole, X., Dadu, R., Lambotte, O., Ramos‐Casals, M., & Suarez-Almazor, M. E. (2021) · Immunotherapy · doi:10.2217/imt-2020-0272 · Cited by 20
Wu, C., Li, Z., Wu, Q., Lin, S., & Xie, X. (2021) · Immunotherapy · doi:10.2217/imt-2020-0230 · Cited by 20
CD8+ T Cell Phenotype and Function in Childhood and Adult-Onset Connective Tissue Disease
Radziszewska, A., Moulder, Z., Jury, E. C., & Ciurtin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911431 · Cited by 20
Les, Í., Pérez-Francisco, I., Cabero, M., Sánchez, C., Hidalgo, M., Teijeira, L., Arrazubi, V., Domínguez, S., Anaut, P., Eguiluz, S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.894550 · Cited by 19
The Current Treatment Landscape of Cutaneous Squamous Cell Carcinoma
Chong, C. Y., Goh, M., Porceddu, S. V., Rischin, D., & Lim, A. M. L. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00742-8 · Cited by 19
Receptor Occupancy Measurement of Anti-PD-1 Antibody Drugs in Support of Clinical Trials
Fu, J., Wang, F., Dong, L., Xing, M.-J., Cheng, X., Wei, S., Xu, J.-Z., Han, M., Dong, K., & Song, H. (2019) · Bioanalysis · doi:10.4155/bio-2019-0090 · Cited by 19
TNF-α inhibitor ameliorates immune-related arthritis and pneumonitis in humanized mice
Gao, J., Miao, J., Sun, H., Fu, X., Zhang, P., Chen, Z., & Zhu, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.955812 · Cited by 19
Guberina, N., Wirsdörfer, F., Stuschke, M., & Jendrossek, V. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100892 · Cited by 18
Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field
Eljilany, I., Castellano, E., & Tarhini, A. A. (2023) · Cancers · doi:10.3390/cancers15164125 · Cited by 21
Computational modeling in melanoma for novel drug discovery
Pennisi, M. A., Russo, G. L., Salvatore, V. D., Candido, S., Libra, M., & Pappalardo, F. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1174688 · Cited by 18
Immune checkpoint inhibitors: a milestone in the treatment of melanoma
Wilden, S. M., Lang, B. M., Mohr, P., & Grabbe, S. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13012 · Cited by 18
Checkpoint‐Inhibitoren in der Immuntherapie: Ein Meilenstein in der Behandlung des malignen Melanoms
Wilden, S. M., Lang, B. M., Mohr, P., & Grabbe, S. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13012_g · Cited by 18
Co‐inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma
Lucca, L. E., & Hafler, D. A. (2017) · Immunological Reviews · doi:10.1111/imr.12529 · Cited by 18
Marinelli, D., Giusti, R., Mazzotta, M., Filetti, M., Krasniqi, E., Pizzuti, L., Landi, L. M., Tomao, F., Cappuzzo, F., Ciliberto, G., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103176 · Cited by 18
Mantia, C. M., & Buchbinder, E. I. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.12.008 · Cited by 18
Self-citationLi, X., Zhou, Y., Xu, B., Qin, Y., Zhao, J., Li, M., Xu, J., & Li, G. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007959 · Cited by 17
The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis
Puri, A., & Homsi, J. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000387 · Cited by 17
Wang, C., Sandhu, J. S., & Fakih, M. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.09.19 · Cited by 17
Shi, J., Niu, J., Shen, D., Liu, M., Tan, Y. K., Li, Y., huang, Y., Cui, L., Guan, Y., & Zhang, L. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13266 · Cited by 17
Rallis, K. S., Makrakis, D., Ziogas, I. A., & Tsoulfas, G. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i6.448 · Cited by 17
Drug Repurposing at the Interface of Melanoma Immunotherapy and Autoimmune Disease
Spitschak, A., Gupta, S. K., Singh, K. P., Logotheti, S., & Pützer, B. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010083 · Cited by 17
Relapse of morphea during Nivolumab therapy for lung adenocarcinoma
Alegre‐Sanchez, A., Fonda‐Pascual, P., Saceda‐Corralo, D., & Heras-Alonso, E. D. L. (2016) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2016.07.013 · Cited by 17
Toxicités dermatologiques des inhibiteurs de checkpoint immunologiques
Sibaud, V., Boulinguez, S., Pagès, C., Riffaud, L., Lamant, L., Chira, C., Boyrie, S., Vigarios, É., Tournier, É., & Meyer, N. (2018) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2018.01.047 · Cited by 17
Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
Bobrowicz, M., Zagożdżon, R., Domagała, J., Vasconcelos‐Berg, R., Guenova, E., & Winiarska, M. (2019) · Cancers · doi:10.3390/cancers11101420 · Cited by 17
Do corticosteroids affect immunotherapy efficacy in malignancy? – A systematic review
Byron, Y., Yegorova‐Lee, S., & Tio, M. (2024) · Cancer Medicine · doi:10.1002/cam4.70254 · Cited by 16
Babey, H., Quéré, G., Descourt, R., Calloch, R. L., Lanfranco, L., Nousbaum, J., Cornec, D., Tison, A., & CHOUAID, C. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1499468 · Cited by 18
Akil, H., Rouanet, J., Viallard, C., Besse, S., Auzeloux, P., Chezal, J., Miot-Noirault, E., Quintana, M., & Degoul, F. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.07.015 · Cited by 16
Shannon, V. R. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000689 · Cited by 16
Neelapu, S. S., Adkins, S., Ansell, S. M., Brody, J., Cairo, M. S., Friedberg, J. W., Kline, J. P., Levy, R., Porter, D. L., van Besien, K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001235 · Cited by 16
Weingarden, A. R., Rubin, S. J. S., & Gubatan, J. M. B. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i8.772 · Cited by 16
Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy
Gupta, A., Shah, U., Khine, H., Vandergriff, T. W., & Froehlich, T. W. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000335 · Cited by 16
Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?
Gediz, F., & Kobak, Ş. (2019) · Current Rheumatology Reviews · doi:10.2174/1573397115666190119094736 · Cited by 16
Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions
NIKE Group, Gallo, M., Guarnotta, V., de Cicco, F., Rubino, M., Faggiano, A., & Colao, A. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02839-w · Cited by 16
Zaremba, A., Chorti, E., Jockenhöfer, F., Bolz, S., Sirin, S., Glas, M., Becker, J. C., Ugurel, S., Roesch, A., Schadendorf, D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0626-9 · Cited by 15
Fujiwara, Y., Horita, N., Harrington, M. D., Namkoong, H., Miyashita, H., & Galsky, M. D. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03203-7 · Cited by 15
Calvo, V., Fernández, M. A., Collazo-Lorduy, A., Franco, F., Núñez, B., & Provencio, M. (2021) · Lung Cancer Management · doi:10.2217/lmt-2021-0003 · Cited by 15
The management of immune-related adverse events associated with immune checkpoint blockade
Fay, A. P., Moreira, R. B., Filho, P. R. S. N., Albuquerque, C., & Barrios, C. H. (2016) · Expert Review of Quality of Life in Cancer Care · doi:10.1080/23809000.2016.1142827 · Cited by 15
Bender, C., Dimitrakopoulou‐Strauss, A., Enk, A., & Hassel, J. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw128 · Cited by 15
Self-citationCancer Therapy with Checkpoint Inhibitors: Establishing a Role for Ophthalmology
Davis, M. E., & Francis, J. H. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.08.003 · Cited by 15
Immunotherapy Management in Special Cancer Patient Populations
Ramnaraign, B. H., Chatzkel, J. A., Al‐Mansour, Z., Rogers, S. C., Jones, D. V., DeRemer, D. L., & George, T. J. (2021) · JCO Oncology Practice · doi:10.1200/op.20.00996 · Cited by 15
McGonagle, D., Bragazzi, N. L., Amital, H., & Watad, . (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102456 · Cited by 14
Desmedt, V., Jauregui-Amezaga, A., Fierens, L., Aspeslagh, S., Dekervel, J., Wauters, E., Peeters, M., Sabino, J., Crapé, L., Somers, M. J. G., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.025 · Cited by 14
Checkpoint inhibitor-associated autoimmunity
Ladak, K., & Bass, A. R. (2018) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.03.009 · Cited by 14
Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management
Williams, S. G., Mollaeian, A., Katz, J. D., & Gupta, S. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1804362 · Cited by 14
Immunotherapy induced enterocolitis and gastritis – What to do and when?
Cheung, V., & Brain, O. (2020) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2020.101703 · Cited by 14
Bender, D. A., Heilbroner, S. P., Wang, T. J. C., Shu, C. A., Hyde, B. B., Spina, C. S., & Cheng, S. K. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001627 · Cited by 14
Briani, C., Ferrari, S., Campagnolo, M., Tagliapietra, M., Castellani, F., Salvalaggio, A., Mariotto, S., Visentin, A., & Cavallaro, T. (2021) · Brain Sciences · doi:10.3390/brainsci11020132 · Cited by 14
Tully, K. H., Cone, E. B., Cole, A. P., Sun, M., Chen, X., Marchese, M., Roghmann, F., Kilbridge, K. L., & Trinh, Q. (2021) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000840 · Cited by 14
Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease
Dietz, H., Weinmann, S. C., & Salama, A. K. S. (2021) · Cancer Management and Research · doi:10.2147/cmar.s283217 · Cited by 14
Yu, Y., Zhou, Y., Zhang, X., Tan, K., Zheng, J., Jia, L., & Cui, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.934093 · Cited by 14
Glehr, G., Riquelme, P., Zhou, J. Y., Cordero, L., Schilling, H., Kapinsky, M., Schlitt, H. J., Geissler, E. K., Burkhardt, R., Schmidt, B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1011040 · Cited by 14
Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014–2021
Xu, Z., Qi, G., Liu, X., Li, Z., Zhang, A., Ma, J., & Li, Z. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281983 · Cited by 14
Sculier, C., Bentea, G. P., Ruelle, L., Grigoriu, B. D., Coureau, M., Gorham, J., Sideris, S., Holbrechts, S., Lafitte, J., Meert, A., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.026 · Cited by 14
Ozawa, N., Yokobori, T., Osone, K., Katayama, C., Suga, K., Komine, C., Shibasaki, Y., Shiraishi, T., Okada, T., Kato, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92530-3 · Cited by 14
Sarcoidosis, Malignancy and Immune Checkpoint Blockade
Gaughan, E. M. (2017) · Immunotherapy · doi:10.2217/imt-2017-0128 · Cited by 14
Dias, Y., Silva, V. A. O., de Carvalho, M. F., Herchenhorn, R., & Herchenhorn, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1712632 · Cited by 13
Ferretti, F., Cannatelli, R., Maconi, G., & Ardizzone, S. (2023) · Cancers · doi:10.3390/cancers15020542 · Cited by 13
Chen, Y., Huang, M., Swetlik, C., Toljan, K., Mahadeen, A. Z., Bena, J., Kunchok, A. C., Funchain, P., & McGinley, M. (2023) · European Journal of Neurology · doi:10.1111/ene.15942 · Cited by 13
Management of gastrointestinal adverse events induced by immune‐checkpoint inhibitors
Wang, Z., & Shen, L. (2018) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2017.12.001 · Cited by 13
Ipilimumab treatment associated with myasthenic crises and unfavorable disease course
Derle, E., & Benli, S. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3471-6 · Cited by 13
Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook
Jin, Z., Shen, J., Wang, C., Chen, D., Zhang, B., Zhang, J., Ajani, J. A., Bennouna, J., Chao, J., Yoon, H. H., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-2804 · Cited by 13
Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy
Ohnuma, K., Hatano, R., Dang, N. H., & Morimoto, C. (2018) · Modern Rheumatology · doi:10.1080/14397595.2018.1532559 · Cited by 13
Li, Y., Kang, X., Wang, H., Guo, X., Zhou, J., Duan, L., Si, X., Zhang, L., Liu, X., Qian, J., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13338 · Cited by 13
Gonzalez-Mazón, I., Sánchez-Bilbao, L., Martín-Varillas, J. L., García‐Castaño, A., Ruiz, M. D., Piña, I. B., Hernández, J. L., Castañeda, S., Llorca, J., González-Gay, M. Á., et al. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/o5nvgv · Cited by 13
Forschner, A., Loquai, C., Meiß, F., Hüning, S., Pawlowski, J., Bradfisch, F., Lehr, S., & Nashan, D. (2021) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14501 · Cited by 13
Immune hemolytic anemia associated with the use of immune checkpoint inhibitors: a scoping review
Hernandez‐Martinez, J., Rios-Garcia, E., Palomares-Palomares, C. B., & Arrieta, O. G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1586426 · Cited by 13
Gelibter, S., Saraceno, L., Susani, E. L., Pirro, F., Sessa, M., & Protti, A. (2024) · European Journal of Neurology · doi:10.1111/ene.16547 · Cited by 12
Cardeña-Gutiérrez, A., & Barahona, M. L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.908752 · Cited by 12
Conundrum for Psoriasis and Thyroid Involvement
Cira, C.-I., Carşote, M., Nistor, C., Petca, A. T., Petca, R., & Şandru, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054894 · Cited by 12
Atypical autoimmune adverse effects with checkpoint blockade therapies
Friedman, C. F., & Snyder, A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw658 · Cited by 12
Rheumatic complications in cancer patients treated with immune checkpoint inhibitors
Lee, K., Kim, H., & Yoon, S. Y. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.060 · Cited by 12
Aggarwal, S. (2019) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_448_19 · Cited by 12
Challenges faced when identifying patients for combination immunotherapy
Ernstoff, M. S., Gandhi, S., Pandey, M. R., Puzanov, I. J., Grivas, P. D., Montero, A. J., Velcheti, V., Turk, M. J., Diaz-Montero, C. M., Lewis, L. D., et al. (2017) · Future Oncology · doi:10.2217/fon-2017-0218 · Cited by 12
Self-citationMazor, R., King, E. M., & Pastan, I. H. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.08.016 · Cited by 11
Toxicities from immunotherapy: From clinical trials to real-world clinical practice
Riveiro‐Barciela, M., Araguás, E. T., Martínez‐Valle, F., Roca-Herrera, M., Zamora, E., Barreira‐Díaz, A., & Muñoz‐Couselo, E. (2020) · Medicina Clínica · doi:10.1016/j.medcli.2020.06.057 · Cited by 11
Gao, C., Gardner, D. B., Theobalds, M.-C., Hitchcock, S., Deutsch, H., Amuzie, C. J., Cesaroni, M., Sargsyan, D., Rao, T. S., & Malaviya, R. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13659 · Cited by 11
Acute and Long-term Adverse Events Associated With Checkpoint Blockade
Davies, M. J. (2019) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2019.08.005 · Cited by 13
Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces
Deligiorgi, M. V., Liapi, C. A., & Trafalis, D. T. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1869211 · Cited by 11
Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors
Park, B. J., Jung, S., Chen, S. T., Dewan, A. K., & Johnson, D. B. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00706-y · Cited by 11
Self-citation
Metadata
- Authors
- Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., Mudigonda, T., Spencer, K., Bender, C., Lee, J., Kaufman, H. L., Menzies, A. M., Hassel, J. C., Mehnert, J. M., Sosman, J. A., Long, G. V., & Clark, J. I.
- Affiliations
- Vanderbilt University Medical Center (US)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
- The University of Sydney (AU)
- Roswell Park Comprehensive Cancer Center (US)
- Rutgers Cancer Institute (US)
- University Hospital Heidelberg (DE)
- Westmead Hospital (AU)
- Loyola University Medical Center (US)
- Corresponding author
- Johnson, Douglas B.
- ORCID
- Johnson, Douglas B.
- Sullivan, Ryan J.
- Ott, Patrick A.
- Carlino, Matteo S.
- Khushalani, Nikhil I.
- Ye, Fei
- Guminski, Alexander
- Puzanov, Igor
- Lawrence, Donald P.
- Buchbinder, Elizabeth I.
- Spencer, Kristen
- Bender, Carolin
- Lee, Jenny
- Kaufman, Howard L.
- Menzies, Alexander M.
- Hassel, Jessica C.
- Mehnert, Janice M.
- Sosman, Jeffrey A.
- Long, Georgina V.
- Clark, Joseph I.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-02-01
- Volume
- 2
- Issue
- 2
- Pages
- 234
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2193769500
- Cited by
- 642
- References
- 30
- Citations by year
- 2026: 13 · 2025: 29 · 2024: 49 · 2023: 44 · 2022: 64 · 2021: 73 · 2020: 94 · 2019: 93 · 2018: 65 · 2017: 68 · 2016: 47
- FWCI
- 26.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (K12 CA 0906525, K12CA090625)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- ipilimumab, advanced melanoma, immune-related adverse events, immune-related colitis, immune-related pneumonitis, immune-related hepatitis, immune-related endocrinopathy, immune-related dermatitis, immune checkpoint inhibitors, immunosuppressive therapy, rheumatoid arthritis, psoriasis, inflammatory bowel disease, systemic lupus erythematosus
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Autoimmune Diseases, Female, Humans, Male, Melanoma, Middle Aged, Retrospective Studies, Risk Factors, Skin Neoplasms, Time Factors, Autoimmunity, Treatment Outcome, Risk Assessment, Patient Selection, Tertiary Care Centers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
